Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population*
- 26 March 1995
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 57 (3) , 265-269
- https://doi.org/10.1016/0009-9236(95)90151-5
Abstract
The occurrence of multiple copies of the CYP2D6 gene was investigated 217 white healthy Spaniards by the combined use of Xba I and Eco RI restriction fragment length polymorphism (RFLP) analyses. About 3.5% of the alleles yielded an 12.1 kb Eco RI-RFLP product in combination with the 42 kb Xba I-RFLP product, which is indicative of multiple CYP2D6. The prevalence of subjects carrying multiple CYP2D6 was 7%. The 12.1 kb Eco RI-RFLP product was highly associated (60%) with the presence of the genotype 29wt/42wt, as characterized by mutation-specific polymerase chain reaction and Xba I-RFLP analyses. Six subjects who had multiple CYP2D6 had other genotypes, namely, 44wt/42wt (four subjects), 29C/42wt (one subject), and one subject had a 12.1 kb product plus the CYP2D6C mutation associated with the 44 kb/42 kb genotype. All subjects identified as carrying multiple CYP2D6 had only two CYP2D6 copies in the same chromosome and were classified as carriers of the (CYP2D6L)2 allelic variant. Phenotyping with debrisoquin indicated an increase in the oxidative capacity as a function of the number of functional CYP2D6 genes. The metabolic ratio and the 95% confidence limits were as follows: subjects lacking functional genes, 48.8 (95% confidence limits, 14.4 to 79.3); subjects with one functional gene, 2.14 (95% confidence limits, 0.61 to 3.67); subjects with two functional genes, 1.5 (95% confidence limits, 0.88 to 2.14); and subjects with three functional genes, 0.33 (95% confidence limits, 0.22 to 0.45).(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 21 references indexed in Scilit:
- The cytochrome P450 CYP2D6 allelic variant CYP 2D6J and related polymorphisms in a European populationPharmacogenetics, 1994
- Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolismPharmacogenetics, 1993
- Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquineThe Lancet, 1993
- Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteersEuropean Journal of Clinical Pharmacology, 1992
- Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotypePharmacogenetics, 1991
- Debrisoquine/Sparteine Hydroxylation Genotype and Phenotype: Analysis of Common Mutations and Alleles ofCYP2D6in a European PopulationDNA and Cell Biology, 1991
- Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypesPharmacogenetics, 1991
- [17] Genetic polymorphism of debrisoquine oxidation: restriction fragment analysis and allele-specific amplification of mutant alleles of CYP2D6Published by Elsevier ,1991
- Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22Genomics, 1988
- A routine method for the establishment of permanent growing lymphoblastoid cell linesHuman Genetics, 1986